Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo October 18, 2024Vol.50 No.39By McKenzie Prillaman
Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer October 18, 2024Vol.50 No.39By Jacquelyn Cobb
Trials & Tribulations Cancer clinical trials shouldn’t discriminate—but they do October 11, 2024Vol.50 No.38By Erin Miller
Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies September 13, 2024Vol.50 No.34By McKenzie Prillaman
Trials & Tribulations A simple intervention could help address overlooked pain among older adults with cancer in rural America September 13, 2024Vol.50 No.34By Megan J. Shen
Trials & Tribulations Is gastrectomy indicated?A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations? September 06, 2024Vol.50 No.33By Rebecca Sutphen, Sue Friedman and Jon Florin
Trials & Tribulations Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC August 02, 2024Vol.50 No.31By Donald A. Berry
Trials & Tribulations Better oncology drug management could lead to improved outcomes, lower costs July 26, 2024Vol.50 No.30By Matt Ingram
NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers June 28, 2024Vol.50 No.26By Matthew Bin Han Ong
Trials & Tribulations The thorny road to drug approval for myelodysplastic syndromes June 14, 2024Vol.50 No.24By Mikkael A. Sekeres
